Design of intramolecularly activated prodrugs

Drug Metabolism Reviews

Volumn 30, Issue 4, 1998, Pages 787-807

  Testa, Bernard ^a   Mayer, Joachim M ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOBENZAMIDE; AMIDE; AMINE; BENZAMIDE DERIVATIVE; CARBAMIC ACID DERIVATIVE; CARBAMIC ACID ESTER; CARBOXYLIC ACID DERIVATIVE; HYDROXYL GROUP; MEQUINOL; PHENOL DERIVATIVE; PILOCARPIC ACID; PILOCARPINE; PRODRUG; PROPIONAMIDE DERIVATIVE;

CYCLIZATION; DRUG ACTIVATION; DRUG DESIGN; DRUG HYDROLYSIS; METHODOLOGY; MOLECULAR INTERACTION; REVIEW;

EID: 0031726953     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.3109/03602539808996330     Document Type: Review

References (31)

1. B. Testa, The Metabolism of Drugs and Other Xenobiotics - Biochemistry of Redox Reactions, Academic Press, London, 1995, Sect. 1.8.
2. N. J. Harper, Drug latentiation, in Progress in Drug Research (E. Jucker, ed.), Birkhäuser, Basel, 1962, Vol. 4, pp. 221-294.
3. V. J. Stella, W. N. A. Charman, and V. H. Naringrekar, Prodrugs: Do they have advantages in clinical practice? Drugs, 29, 455-473 (1985).
4. H. Bundgaard, A. B. Hansen, and H. Kofod (eds.), Optimization of Drug Delivery, Munkgaard, Copenhagen, 1982.
5. R. T. Borchardt, A. J. Repta, and V. J. Stella (eds.), Directed Drug Delivery - A Multidisciplinary Approach, Humana Press, Totowa, NJ, 1985.
6. C. G. Wermuth, Designing prodrugs and bioprecursors, in Drug Design: Fact or Fantasy? (G. Jolles and K. R. H. Woolridge, eds.), Academic Press, London, 1984, pp. 47-72.
7. K. J. Widder and R. Green (eds.), Drug and Enzyme Targeting, Methods in Enzymology, Volume 112, Academic Press, Orlando, FL, 1985.
8. S. Y. Chan and A. Li Wan Po, Prodrugs for dermal delivery, Int. J. Pharmaceut., 55, 1-16 (1989).
9. D. G. Waller and C. F. George, Prodrugs, Br. J. Clin. Pharmacol., 28, 497-507 (1989).
10. S. Gangwar, G. M. Pauletti, B. Wang, T. J. Siahaan, V. J. Stella, and R. T. Borchardt, Prodrug strategies to enhance the intestinal absorption of peptides, Drug Discov. Today, 2, 148-155 (1997).
11. B. Testa, Drug metabolism, in Burger's Medicinal Chemistry and Drug Discovery, 5th ed. (M. E. Wolff, ed.), Wiley, New York, 1995, Vol. 1, pp. 129-180.
12. L. P. Balant and E. Doelker, Metabolic considerations in prodrug design, in Burger's Medicinal Chemistry and Drug Discovery, 5th ed. (M. E. Wolff, ed.), Wiley, New York, 1995, Vol. 1, pp. 949-982.
13. B. Testa and J. Caldwell, Prodrugs revisited - The "ad hoc" approach as a complement to ligand design, Med. Res. Rev., 16, 233-241 (1996).
14. M. I. Page, D. Render, and G. Bernath, Stereochemical studies. Part 112. Geometrical dependence of intramolecular catalysis in the hydrolysis and aminolysis of aryl esters, J. Chem. Soc. Perkin Trans. II, 867-871 (1986).
15. H. Bundgaard, C. Larsen, and E. Arnold, Prodrugs as drug delivery systems XXVII. Chemical stability and bioavailability of a water-soluble prodrug of metronidazole for parenteral administration, Int. J. Pharmaceut., 18, 79-87 (1984).
16. G. N. Wernly-Chung, J. M. Mayer, A. Tsantili-Kakoulidou, and B. Testa, Structure-reactivity relationships in the chemical hydrolysis of prodrug esters of nicotinic acid, Int. J. Pharmaceut., 63, 129-134 (1990).
17. D. Shan, M. G. Nicolaou, R. T. Borchardt, and B. Wang, Prodrug strategies based on intramolecular cyclization reactions, J. Pharm. Sci., 86, 765-767 (1997).
18. W. S. Saari, J. E. Schwering, P. A. Lyle, S. J. Smith, and E. L. Engelhardt, Cyclization-activated prodrugs. Basic esters of 5-bromo-2′-deoxyuridine, J. Med. Chem., 33, 2590-2595 (1990).
19. W. S. Saari, J. E. Schwering, P. A. Lyle, S. J. Smith, and E. L. Engelhardt, Cyclization-activated prodrugs. Basic carbamates of 4-hydroxyanisole, J. Med. Chem., 33, 97-101 (1990).
20. K. F. Thomsen, F. Strøm, B. V. Sforzini, M. Begtrup, and N. Mørk, Evaluation of phenyl carbamates of ethyl diamines as cyclization-activated prodrug forms for protecting phenols against first-pass metabolism, Int. J. Pharmaceut., 112, 143-152 (1994).
21. K. F. Thomsen and H. Bundgaard, Cyclization-activated phenyl carbamate prodrug forms for protecting phenols against first-pass metabolism, Int. J. Pharmaceut., 91, 39-49 (1993).
22. K. Fredholt, N. Mørk, and M. Begtrup, Hemiesters of aliphatic dicarboxylic acids as cyclization-activated prodrug forms for protecting phenols against first-pass metabolism, Int. J. Pharmaceut., 123, 209-216 (1995).
23. A. Vigroux, M. Bergon, and C. Zedde, Cyclization-activated prodrugs: N-(Substituted 2-hydroxyphenyl and 2-hydroxypropyl)carbamates based on ring-opened derivatives of active benzoxazolones and oxazolidinones as mutual prodrugs of acetaminophen, J. Med. Chem., 38, 3983-3994 (1995).
24. H. Bundgaard, E. Falch, C. Larsen, G. L. Mosher, and T. J. Mikkelson, Pilocarpine prodrugs. II. Synthesis, stability, bioconversion, and physicochemical properties of sequentially labile pilocarpine acid diesters, J. Pharm. Sci., 75, 775-783 (1986).
25. N. M. Nielsen and H. Bundgaard, Prodrugs as drug delivery systems. 42. 2-Hydroxymethylbenzamides and 2-acyloxymethylbenzamides as potential prodrug forms for amines, Int. J. Pharmaceut., 29, 9-18 (1986).
26. K. L. Amsberry, A. E. Gerstenberger, and R. T. Borchardt, Amine prodrugs which utilize hydroxy amide lactonization. II. A potential esterase-sensitive amide prodrug, Pharm. Res., 8, 455-461 (1991).
27. B. Wang, H. Zhang, and W. Wang, Chemical feasibility studies of a potential coumarin-based prodrug system, Bioorg. Med. Chem. Lett., 6, 945-950 (1996).
28. G. M. Pauletti, S. Gangwar, B. Wang, and R. T. Borchardt, Esterase-sensitive cyclic prodrugs of peptides: Evaluation of a phenylpropionic acid promoiety in a model hexapeptide, Pharm. Res., 14, 11-17 (1997).
29. B. Wang, W. Wang, H. Zhang, D. Shan, and T. D. Smith, Coumarin-based prodrugs 2. Synthesis and bioreversibility studies of an esterase-sensitive cyclic prodrug of DADLE, an opioid peptide, Bioorg. Med. Chem. Lett., 6, 2823-2826 (1996).
30. C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Deliv. Rev., 23, 3-25 (1997).
31. B. Testa and J. M. Mayer, Hydrolysis in Drug and Prodrug Metabolism -The Biochemistry and Enzymology of Hydrolases, Verlag Helvetica Chimica Acta (in press).